PD-1/PD-L1 inhibitors
Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
1. A compound which is:
or a pharmaceutically acceptable salt thereof.
2. A compound which is:
or a pharmaceutically acceptable salt thereof.
3. A compound which is:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
5. The pharmaceutical composition according to claim 4 , further comprising at least one additional anticancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, atezolizumab, and ipilimumab.
6. The pharmaceutical composition according to claim 5 , wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
7. A pharmaceutical composition comprising the compound of claim 2 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
8. The pharmaceutical composition according to claim 7 , further comprising at least one additional anticancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, atezolizumab, and ipilimumab.
9. The pharmaceutical composition according to claim 8 , wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
10. A pharmaceutical composition comprising the compound of claim 3 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
11. The pharmaceutical composition according to claim 10 , further comprising at least one additional anticancer agent selected from rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, atezolizumab, and ipilimumab.
12. The pharmaceutical composition according to claim 11 , wherein the additional anticancer agent is nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
13. A method for inhibiting Programmed death-1 (PD-1), Programmed death-ligand 1 (PD-L1) and/or the PD-1/PD-L1 interaction comprising administering the compound of claim 1 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
14. A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering the compound of claim 2 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
15. A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering the compound of claim 3 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
16. A method for treating hepatitis B virus (HBV) comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
17. A method for treating hepatitis B virus (HBV) comprising administering a therapeutically effective amount of the compound of claim 2 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
18. A method for treating hepatitis B virus (HBV) comprising administering a therapeutically effective amount of the compound of claim 3 or a pharmaceutically acceptable salt thereof, to a patient in need thereof.